Krug, U., Ravandi, F., Ritchie, E. K., Sayar, H., Lancet, J. E., Craig, M. D., … Stuart, R. K. (2015). Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study. In Oncology Research and Treatment (Vol. 38, pp. 121–121). KARGER.

Krug, U., F. Ravandi, E. K. Ritchie, H. Sayar, J. E. Lancet, M. D. Craig, N. Vey, et al. “Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study.” In Oncology Research and Treatment, 38:121–121. KARGER, 2015.

Krug U, Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, et al. Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study. In: Oncology Research and Treatment. KARGER; 2015. p. 121–121.

Krug, U., et al. “Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study.” Oncology Research and Treatment, vol. 38, KARGER, 2015, pp. 121–121.

Krug U, Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst H-A, Recher C, Klimek VM, Cortes J, Roboz GJ, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Kantarjian HM, Stuart RK. Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study. Oncology Research and Treatment. KARGER; 2015. p. 121–121.